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the world. Within days to weeks of an extremity amputation, up to 80% of these
individuals develop neuropathic pain presenting as phantom limb pain (PLP). The
level of PLP increases significantly by one year and remains chronic and severe for
about 10% of individuals. PLP has a serious negative impact on individuals’ lives.
Current pain treatment therapies, such pharmacological approaches provide limited to
no pain relief, some other techniques applied to the central nervous system (CNS) and
peripheral nervous system (PNS) reduce or block PLP, but none produces long-term
pain suppression. Therefore, new drugs or novel analgesic methods must be developed
that prevent PLP from developing, or if it develops, to reduce the level of pain. This
paper examines the potential causes of PLP, and present techniques used to prevent
the development of PLP, or if it develops, to reduce the level of pain. Finally it presents
a novel technique being developed that eliminates/reduces chronic neuropathic pain
and which may induce the long-term reduction/elimination of PLP.

Background

In the United States, more than 1.7 million people
(0.5% of the population) are living with a lost limb,
and this number is expected to double by 2050 [1].
Within days to weeks of an extremity amputation, up
to 93% of individuals with an amputation experience
one or more type of amputation-related pain [2]. Up to
85% develop neuropathic pain presenting as phantom
limb pain (PLP) [3-8]. Although PLP may not present
for months or years [9], its severity generally increases
significantly over the first year following an amputation
[4, 10], and has a lifetime duration [11]. For those
with an amputation up to 10% suffer severe chronic
PLP [4, 10, 12].
PLP has a serious negative impact on an individual’s
quality of life, by being physically and mentally
debilitating, negatively affects not only an individual’s

potential to perform self-care, and their daily living
activities essential for personal and economic
independence. In addition, it may lead to depression
and feelings of hopelessness. Pain is also a serious
challenge for the sufferer’s caregiver support system
while causing significant general societal and economic
challenges. In the U.S. alone, the annual cost of dealing
with neuropathic pain is estimated at more than
$100 billion [13]. This amount is increased by costs
associated with coping with PLP. Thus, PLP treatment
remains a significant challenge and it remains essential
to improve the quality of life of individuals suffering
PLP.
While PLP is known to be associated with a
number of cellular, neural circuit, and gene changes,
few clinically applied techniques significantly alter
these injury-induced changes leading to long-term
blockade of the pain triggers or a reversal their
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influences [14, 15]. Thus, pain relief is at best temporary. Therefore, it is critical to develop novel
pharmacological or other types of treatment that prevent
the development of PLP following an amputation, or
eliminate PLP once it has developed.
What is PLP?
PLP is a type of neuropathic pain associated with
extremity amputations. PLP presents as burning,
boring, shooting, “pins and needles”, throbbing,
crushing, or an electric shock. Other amputated
limb-associated pains are residual limb pain, and
phantom limb telescoping pain, where the level of
pain increases as the apparent limb becomes shorter
[16–18]. PLP must be distinguished from phantom limb
sensation. Phantom limb sensations are significantly
more benign than PLP, manifesting as the sensation
or perception of movement coming from the missing
limb or body part.
Risk factors for PLP include upper extremity
amputation, bilateral amputations, the presence of
pre-amputation pain, residual pain in the remaining
limb, and increasing time post amputation [19]. The
presence of chronic pain prior to an amputation does
not appear to be associated with an increased level of
late persistent PLP [8].

2
2.1

Causation of PLP
CNS changes

Cortical reorganization
The experience of neuropathic and PLP differ greatly,
with neuropathic pain being associated with the
injured nerve, while for patients with PLP the pain is
ascribed to a specific portion of the missing appendage. This difference suggests that the development
of PLP involves neurological changes associated with
both the peripheral portion of the damaged nerves
and their CNS connections.
Magnetoencephalography (MEG) and magnetic
resonance imaging (MRI) studies on amputees indicate
a positive correlation between the development of
PLP and the development and extent of cortical
reorganization [20]. This observation gave rise to the
theory that maladaptive CNS plasticity remodeling
underlies PLP [17, 21]. This theory holds that maladap-

27
tive plasticity results from the loss of afferent inputs
from the amputated limb giving rise to changes in
neurons and neural circuits in the brain and spinal
cord [15, 19, 21, 22]. This involves afferent brain areas
becoming enlarged, or that there is a shift in neuron
activation into somatotopically organized deafferented
brain areas, with the extent of the shift being positively
associated with PLP intensity [23, 24]. According to
this hypothesis eliminating neuropathic pain requires
the application of techniques to the PNS, while
eliminating PLP requires turning off pain triggers in
both the PNS and CNS.
Although some fMRI studies support this concept
[25, 26], others show no significant relationship between
pain and cortical reorganization [27]. Therefore, the
strength of the argument for a direct relationship
between chronic pain intensity and cortical reorganization after deafferentation is weakening [19]. Considering
this emerging controversy, it is not clear whether the
cortical changes have a causal relationship to PLP or
are merely associated with PLP. Therefore, it is possible
that techniques applied only to peripheral nerves
could prevent the development of, or fully eliminate,
PLP once it has developed, despite the persistence of
CNS reorganization [19].
2.2

PNS changes

Mechanical irritation
Following a peripheral nerve transection, the axons
normally sprout and regenerate to their targets.
However, they may also form a neuroma [28]. While
neuroma formation is a benign process, it can induce
pain if it ensheathes nerve ends in scar tissue due to
excessive fibrous tissue proliferation and perineural
cell overgrowth. This scar tissue can trap the ends of
axons in an area of frequent contact or high pressure,
such as a limb stump [28]. In addition, over time,
the scar tissue can contract, placing the axons under
constant pressure and causing them to become
chronically inflamed, giving rise to chronic pain [29],
thereby inducing mechanical activation of the nociceptive axons. Thus, symptomatic neuromas that form
in the nerve stumps following an amputation are
considered one of the significant triggers underlying
the induction and maintenance of chronic PLP. This
suggests that preventing the formation of symptomatic
neuromas, or eliminating them once they have formed,
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may respectively prevent or eliminate mechanical
or inflammatory nociceptive neuron activation and
causation of PLP.
While neuromas are associated with PLP, PLP can
develop within hours of an amputation, which is before
a neuroma can form. This indicates that although
neuromas are associated with PLP, there are other
triggers for PLP, which are discussed later, such as
the up-regulation of the synthesis and insertion of
voltage-gated sodium channels into nociceptive
neuron causing them to exhibit spontaneous ectopic
electrical activity that underlies PLP [7].
Inflammation and chronic ectopic spontaneous electrical
activity
Numerous experimental studies have demonstrated
that pro-inflammatory cytokines released in the region
of an injury induce or facilitate neuropathic pain
and hyperalgesia. Among the critical cytokines are
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α) [30, 31]. These cytokines
act on both peripheral axons and central axons
and neurons [31]. TNF-α induces pain by inducing
nociceptive neuron up-regulation of genes for the
transcription of voltage-gated sodium ion channels
(NaV) [32]. When these channels are inserted into the
neuron membrane they cause chronic spontaneous
ectopic electrical activity [33, 34].
Pro-inflammatory cytokines also act centrally to
induce sensitization of dorsal root ganglion (DRG)
neurons [35], and pain-modulating neurons in the
rostral ventromedial medulla [36]. Pro-inflammatory
cytokines are also released from inflamed skin [37].
Thus, a localized inflammatory response can induce
chronic pain [38]. Further, this response can be evoked
by these cytokines even in the absence of nerve damage
[38]. This suggests that following wound healing,
inflammatory cytokines can cause spontaneous ectopic
electrical activity of nociceptive neurons and the
generation of chronic neuropathic pain, as well as
contribute to PLP [38].

3

Reducing / eliminating PLP

3.1

Pharmacological interventions

The standard of care for treating PLP is the administration of anticonvulsants, anti-depressants, and

analgesics such as gabapentin and morphine with the
goal of suppressing PLP [4]. Gabapentin has variable
influences on PLP [39-41], dextromethorphan may be
effective [42], but memantine is not effective [43].
Antidepressants, anticonvulsants, opioids, and NMDA
receptor antagonists are somewhat effective and
induce more reliable analgesia [7, 44, 45]. However,
not all subjects may be sensitive to the drugs, the
drugs may have only a short-lived influence, or their
side effects may preclude their use [46-49]. While new
drugs and techniques are being developed and tested,
the efficacy evidence for these treatment modalities
is inconclusive.
3.2

Modifying CNS neural circuits

When pharmacological interventions are not effective,
other approaches may be required to suppress PLP.
The maladaptive changes that develop following an
amputation are in part related to the loss of GABAergic
inhibition, glutamate-mediated long-term potentiationlike changes, and changes in neuronal connectivity,
including axonal sprouting. These observations gave
rise to the hypothesis that behavioral interventions
might suppress PLP. Effective techniques for preventing PLP from developing, or suppressing PLP once
it has developed include biofeedback [50], acupuncture
[51–53], with some but limited evidence for hypnosis
[54–56], biofeedback [57], sensory motor training
[58], psychological interventions [59, 60], and coping
mechanisms [61].
Additional techniques effective against PLP include
mirror box therapy, which involves visuomotor training
of motor cortex activity, and results in restoring the
body image in the M1 region of the motor cortex by
restoring the original missing limb cortical representation, thus tricking the brain into thinking the missing
limb is present [62–66], computerized visuo-motor
training [63], and transcutaneous electrical nerve
stimulation (TENS), which appears to interrupt pain
signals before they get to the spinal cord and cortex
[67–69]. Electrical stimulation of the spinal cord [70],
and brain [71, 72], have the goal of suppressing PLP by
altering the activity of nerve trauma-induced altered
neural circuits. These studies support the hypothesis
that changes in CNS neural circuits and activity
underlie the etiology of PLP and that altering or
reversing these maladaptive changes by inducing new
Journal of Neurorestoratology
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CNS inputs can reduce PLP. Although these techniques
may reduce PLP, none induces optimal long-term
clinical pain relief.
3.3

Neuromas

Virtually all subjects suffering PLP have a symptomatic neuroma. Removing the neuroma eliminates
PLP [73]. However, 42% of the patients redevelop a
symptomatic neuroma and persistent pain within 37
months [74]. Therefore, while important, neurectomy
alone is not the optimal long-term PLP treatment.
The pain relief provided by a neurectomy can be
increased by performing a high traction neurectomy,
which involves holding the nerve under traction,
cutting away the neuroma high on the nerve, and
then implanting the nerve stumps into soft target
tissues. Effective targets include fat [75], veins [76, 77],
and muscle [78].
Relief from PLP can also be achieved by coaptating
the proximal nerve stumps, which involves anastomosing two freshly transected proximal nerve stumps
[79, 80]. A third approach, for reducing PLP involves,
at the time of an amputation, securing the exposed
nerve stump in an empty collagen nerve tube. This
reduces the level of PLP that develops by 64% compared to that following traction neurectomy [79]. These
results suggest that a significant component of the
causation of PLP lies in the periphery, and is associated
with changes nociceptive neurons changes.
3.4

Anti-inflammatory mediators

Neuropathic pain can be reduced by the application
of cytokines with apparently opposite initial actions.
Pro-inflammatory cytokines, such as tumor necrosis
factor-α (TNF-α), interleukin-1β (IL-1β), insulin like
factor-1 (ILF-1), and insulin like factor-6 (ILF-6),
enhance the inflammatory state of nerve stumps.
However, this pro-inflammatory action triggers a poorly
understood physiological mechanism causing the site
to transition from a pro- to an anti-inflammatory state
in which the pain is eliminated [81, 82].
By a slower process, chronic neuropathic pain can
be eliminated by the application of interleukin-10
(IL-10) and transforming growth factor-β1 (TGF-β1).
They act by: (1) blocking gene transcription for the
expression of receptors for pro-inflammatory cytokines
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[83], (2) blocking the synthesis and release of proinflammatory cytokines from injury site macrophages,
neutrophils and mast cells that activate those receptors
[84], (3) up-regulating the release of endogenous antiinflammatory cytokines [85-88], and (4) inducing the
expression and release of the anti-inflammatory
mediator IL-1 receptor agonist 6 (IL-1ra6), thus blocking
IL-1β-mediated pain [89-91].
3.5

Blocking spontaneous ectopic electrical activity

As stated, chronic neuropathic pain results from
nociceptive neuron spontaneous ectopic electrical
activity triggered by injury/cytokine-induced release
of TNF-α. TNF-α application leads to pain by inducing
the up-regulation of gene transcription for voltagegated sodium ion channels (NaV). When inserted into
the membranes of nociceptive neurons, these channels
cause chronic spontaneous ectopic electrical activity.
The resulting pain can be blocked the application
of IL-10, which down-regulates the synthesis of the
NaV channels resulting in silencing the nociceptive
neurons [92, 93].
3.6 Physiological source of pro- and anti-inflammatory
cytokines and other mediators
All the cytokines and other mediators that induce
the changes required to eliminate pain are contained
in, and released by, platelets. This knowledge has
led to many studies testing the efficacy of applying
autologous platelet-rich plasma (PRP) to pain sites for
their ability to reduce/eliminate chronic neuropathic
pain. Some studies involving the systematic comparative analyses of such studies concluded that PRP is
effective in reducing/eliminating pain [94–97]. However,
other similar studies concluded that, although the
evidence is strong, the statistical evidence is not
sufficient to support the hypothesis [98–101].
The variability in analgesic effects of PRP observed
in different studies is best explained by the significant
differences in the studies in PRP composition and
application. Thus, the PRP prepared using different
PRP separation devices differs greatly in platelet
concentration, the concentration and composition of
platelet factors, and the bioactivity of those factors.
Thus, some applied PRP may lack the capacity to
reduce pain [81]. It appears that reliable and consistent

Journal of Neurorestoratology

30
levels of PRP-induced analgesia will be achieved
once PRP preparation and applications protocols are
standardized.
3.7

Local and regional anesthesia

The local anesthetic lidocaine, a sodium channel
blocker, blocks PLP pain [3]. However, more effective
analgesia of PLP is achieved using regional anesthesia
of an amputation stump, such as by brachial plexus
blockade. This eliminates PLP in 50% of the patients
[102]. While individuals who continue to manifest
PLP following regional anesthesia show no cortical
reorganization, for those who achieve pain reduction,
it is mirrored by the rapid elimination of the cortical
reorganization in somatosensory cortex [102,103].
Another peripheral oriented technique for reducing
PLP is the use of electrical prostheses [25], and sensory
stimulation [104]. Finally, pre-amputation lumbar
epidural blockade with bupivacaine and morphine
reduce the incidence of PLP in the first year after
operation [105]. The mechanism by which preamputation anesthesia is effective has not been
elucidated.
3.8 Novel technique for reducing/eliminating
chronic neuropathic pain
PRP within a collagen tube has been used to promote
the regeneration of axons across peripheral nerve gaps.
After removing existing neuromas, the proximal and
distal nerve stumps were secured within a collagen
tube and the tube filled with PRP (Fig. 1). This
induced neurological recovery in 100% of the subjects,
even under conditions where standard nerve repair
techniques involving bridging nerve gaps with a
sensory nerve graft are not effective in inducing axon
regeneration and neurological recovery [106–108].

Fig. 1

In the study promoting nerve regeneration using
PRP, prior to the nerve repair surgery, 75% of the
patients were suffering chronic mild to excruciating
chronic neuropathic pain. Within 3 weeks of the nerve
repairs, and prior to any neurological recovery, the
pain of 94% of the patients was eliminated, while for
6% it had been reduced to tolerable [109]. No pain
returned more than 3 years post-surgery [108].
For technical reasons, for one patient, no attempt
was made to repair the nerve gap. However, because
the patient was suffering excruciating neuropathic
pain, the proximal nerve stump was secured within a
closed ended collagen tube filled with PRP. The pain
was eliminated and did not return after more than 3
years (Fig. 2) [108].
3.9

Can PRP prevent the development of PLP?

The observed efficacy of PRP in reducing chronic
neuropathic pain suggests that it might be similarly
effective in preventing the development of PLP, or
reducing/eliminating PLP once it has developed. This
could be tested if, at the time of an amputation, the
major exposed nerve stumps were secured in a closeended collagen tube filled with PRP. The number of
treated nerve stumps would depend on whether the
amputation is of an upper or lower appendage, and
whether high or low on the appendage. Thus, for an
upper or lower arm, there would be 3 nerves (radial,
median, ulnar), while for the upper and lower leg,
there would be 1 and 4 nerves respectively (sciatic vs.
tibial, sural, peroneal, saphenous).
3.10

Proposed mechanisms of action

A number of mechanisms can be proposed by which
PRP may prevent the development of PLP. (1) Securing
nerve stumps within a collagen tube filled with PRP
may prevent or reduce neuroma formation, thus

Photograph of a radial nerve with an 8-cm long gap, where both stumps were secured inside a collagen tube filled with autologous

PRP. Prior to surgery this nerve was evoking excruciating chronic neuropathic pain, but by 4-months post repair, the patient suffered no
pain, was off all analgesics, and no pain returned during the following 3 years. The two white arrows indicate the ends of the collagen
tubes into which the nerve stumps were secured with sutures. NOTE: The 4 cm × 8 cm collagen sheet was sewn into a tube.
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Photograph of the treatment of the proximal nerve stump of a radial nerve causing severe chronic neuropathic pain secured within

the end of a collagen tube filled with PRP (black line delineates the PRP-filled collagen tube) The proximal end of the collagen tube is
marked by the arrowhead and the closed distal end with a suture (arrow). The excruciating chronic neuropathic pain was eliminated
within 2 months.

keeping transected axons from becoming trapped
within an inflammatory and scar tissue environment.
(2) PRP released pro-inflammatory cytokines may promote the development of an enhanced inflammatory
state, which, in turn, induces a rapid transition of
the nerve stump environment from pro- to an antiinflammatory. (3) PRP-released factors may block the
synthesis and release of pro-inflammatory cytokines
from cells residence at the injury site. (4) PRP-released
factors may block gene transcription for receptors
for pro-inflammatory cytokines. (5) PRP-released antiinflammatory cytokines and other mediators may
induce the release of endogenous anti-inflammatory
cytokines and the expression and development of an
anti-inflammatory receptor agonist. (6) PRP-released
factors may eliminate nociceptive chronic neuron
spontaneous ectopic electrical activity. Thus, one or
more of these mechanisms should promote an antiinflammatory state in which the nociceptive neurons
are not spontaneously active and are free from
mechanical activation thus preventing or eliminating
PLP.

4

Discussion

Following an amputation, chronic PLP becomes
manifest in association with the development of
proximal nerve stump neuromas, chronic peripheral
nerve inflammation, nociceptive neuron chronic

ectopic spontaneous electrical activity, and cortical
reorganization. While the pain associated with PLP is
evoked by peripheral triggers, the ability to ascribe the
PLP to specific sensory modalities or specific missing
tissues appears to result from the cortical reorganization
caused by the loss of afferent inputs from the missing
appendage. This raises the question of whether PLP
results from PNS, CNS, or both PNS and CNS triggers.
Similarly, there is a dispute as to whether complete
and permanent PLP elimination can be achieved by
applying techniques to only peripheral nerve stumps
or the CNS, or must be applied to both.
This paper examines techniques tested for their
ability to reduce or eliminate PLP. Clinical studies
show that techniques applied to the CNS, such as
mirror box therapy, pharmacological agents, electrical
stimulation and hypnosis reduce PLP for a limited
time. Thus, techniques applied solely to the CNS can
reduce PLP.
Clinical studies have also shown that techniques
applied solely to peripheral nerve stumps reduce/
eliminate PLP as well as prevent PLP from developing.
Thus, removing the neuroma from their proximal
nerve stumps eliminates PLP [110,111]. PLP can be
prevented from developing by securing nerve stumps
inside an empty collagen tube can prevent the
development of PLP [79, 110, 112], and implanting
nerve stumps into soft tissue such as fat [113], veins
[114], and muscle [115], and inside an empty collagen
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tube. Additional effective techniques for preventing
PLP development include the administration of a
local anesthesia [116], and regional anesthesia [102].
These results indicate that PLP can be eliminated or
prevented from developing by techniques applied
to peripheral nerves. However, because anesthesia
only blocks PLP in about 50% of patients [102], this
indicates that triggers other than nociceptive neuron
spontaneous electrical activity are also responsible
for PLP. But it is not clear whether these triggers lie
in the CNS or PNS.
The observed efficacy of PRP in inducing the longterm elimination of chronic neuropathic pain suggests
that following an amputation securing the major
exposed nerve stumps in a collagen tube filled with
PRP may lead to preventing the development of PLP.
It also suggests that securing the nerve stumps of
individuals suffering PLP in a collagen tube filled
with PRP may eliminate PLP once it has developed.
The paper explores mechanisms by which plateletreleased cytokines and other mediators can exert these
influences. In conclusion, this paper hypothesizes
that application of PRP to nerve stumps prior to the
development of PLP, or after PLP has developed, may
respectively permanently prevent PLP from developing
or permanently eliminate PLP.
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